Open AccessTreatment of patients with cancer using PD‑1/PD‑L1 antibodies: Adverse effects and management strategies (Review)
Author(s) -
Guangshun Sun,
Hanyuan Liu,
Xuesong Shi,
Pengyu Tan,
Weiwei Tang,
Xin Chen,
Guoqiang Sun,
Weijun Yang,
Xiangyi Kong,
Zhiying Zheng,
Hongyong Cao,
Guoqiang Shao
Publication year - 2022
Publication title -
international journal of oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.405
H-Index - 122
ISSN - 1019-6439
DOI - 10.3892/ijo.2022.5364
Subject(s) - durvalumab , nivolumab , pembrolizumab , atezolizumab , avelumab , adverse effect , cancer , immunotherapy , immune system , cancer immunotherapy , oncology , medicine , immunology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom